Obesity and Overweight
Conditions
Brief summary
Context: Obesity, defined as excessive body fat, can lead to disability and loss of autonomy. If there is concomitant quantitative and qualitative muscle loss, sarcopenic obesity (SO) is suspected in this context. Although this clinical entity was defined several years ago, it is only very recently that precise assessment criteria have been established for screening and diagnosing this pathology (Donini et al. 2022). Defined by the ESPEN/EASO consensus, SO has various consequences for health, particularly in terms of mobility and worsening of co-morbidities. It is therefore necessary to screen for SO, to determine its prevalence in the general population and to identify the determining factors in the loss of muscle mass during obesity. Most studies on the prevalence of sarcopenic obesity focus on the elderly population, bearing in mind that the prevalence of this syndrome in the elderly will increase rapidly as a result of the shift in the incidence of obesity from adults to this population in the coming decades. The aim of this project is to determine the prevalence and determining or predisposing factors for sarcopenic obesity in a population of obese people in a broad age range (18-70 years). Longitudinal follow-up of this cohort is planned in order to assess multifactorial changes (body composition, muscle function and physical performance) at 5 and 10 years after their inclusion in the OBESAR-2 study. In addition, patients who have undergone bariatric surgery will also be followed in the shorter term to analyse the phenotypic changes induced by rapid weight loss on muscle loss.
Interventions
\- Blood sampling, urine sampling and tissue sampling
Sponsors
University Hospital, Clermont-Ferrand
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age: 18-70 * Sex: men and women * Clinical nutrition patient receiving a metabolic assessment to optimise clinical and paraclinical management * Patient meeting obesity criteria defined by BMI \> 30 kg/m². * Patient of legal age who has given free, informed and signed consent * Patient covered by social security Non-inclusion criteria : * Patients with cancer or severe chronic disease (renal failure, respiratory failure, liver failure) * Patients with neuromuscular disease * Patient with total walking disability * Patients who are minors * Patient refusing to take part in the study * Pregnant or breast-feeding women * Under guardianship, curatorship, deprived of liberty or under court protection * Patient who has taken part in the OBESAR study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To estimate the prevalence of sarcopenia in a population of adult subjects with obesity, at baseline and at 5 and 10 years. | Day 1 / 5 years /10 years | The primary endpoint is the presence of sarcopenic obesity at inclusion, 5 years and 10 years post-inclusion, assessed according to the latest current recommendations, i.e. impaired muscle function and impaired body composition (Donini et al. 2022). A patient presents with sarcopenic obesity when there is an alteration in muscle function AND an alteration in body composition. For impaired muscular function, strength measured with the handgrip is considered pathological when it is less than 27kg for men and less than 16kg for women. Altered body composition is considered to exist when fat mass is greater than 39, 41 and 43% for women aged between 20 and 39, 40 and 59, and 60 and 79 respectively, and greater than 26, 29 and 31% for men aged between 20 and 39, 40 and 59, and 60 and 79 respectively, AND SMM/W (Skeletal Muscle Mass/Weight) is less than 37% in men and 27.6% in women. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the degree of severity of sarcopenic obesity over time using the ESPEN/EASO consensus staging system in the subgroup of patients undergoing bariatric surgery. | Day 1 /Day of surgery/ 6 months after surgery/ 12 months after surgery/ 5 years /10 years] | — |
| % of patients with the factors associated with sarcopenia | Day 1 / 5 years /10 years | Study the factors associated with sarcopenia by considering the clinical and biological characteristics of obese patients. |
| concentration of biomarkers in a group of obese patients with sarcopenia using the biobank. | Day 1 / 5 years /10 years | Identify plasma, serum, genetic and urinary biomarkers in a group of obese patients with sarcopenia using the biobank. |
| Evaluate the degree of severity of sarcopenic obesity over time using the ESPEN/EASO consensus staging system. | Day 1 / 5 years /10 years | — |
| % change of parameters measured to identify the group at risk of accelerated decline | 5 years /10 years | Evaluate 5- and 10-year trends in anthropometric measurements, muscle function, metabolic parameters and body composition to estimate the group at risk of accelerated decline |
| concentration of biomarkers in a group of obese patients with sarcopenia using the biobank in the subgroup of patients undergoing bariatric surgery. | Day 1 /Day of surgery/ 6 months after surgery/ 12 months after surgery/ 5 years /10 years] | Identify plasma, serum, genetic and urinary biomarkers in a group of obese patients with sarcopenia using the biobank. |
| % of risk of various health problems (diabetes, hypertension, etc.) between sarcopenic and non-sarcopenic patients. | Day 1 / 5 years /10 years | Study the risk of various health problems (diabetes, hypertension, etc.) between sarcopenic and non-sarcopenic patients. |
| % of patients with the factors associated with sarcopenia in the subgroup of patients undergoing bariatric surgery. | Day 1 /Day of surgery/ 6 months after surgery/ 12 months after surgery/ 5 years /10 years] | Study the factors associated with sarcopenia by considering the clinical and biological characteristics of obese patients. |
| % of evolution of biomarkers in the subgroup of patients undergoing bariatric surgery. | Day 1 /Day of surgery/ 6 months after surgery/ 12 months after surgery/ 5 years /10 years | Evaluate changes in plasma, serum, genetic and urinary biomarkers in the same population 5 and 10 years after the inclusion visit, and assess the relationship between changes in biomarkers and changes in sarcopenia using the biobank. |
| % of risk of various health problems (diabetes, hypertension, etc.) between sarcopenic and non-sarcopenic patients in the subgroup of patients undergoing bariatric surgery. | Day 1 /Day of surgery/ 6 months after surgery/ 12 months after surgery/ 5 years /10 years] | Study the risk of various health problems (diabetes, hypertension, etc.) between sarcopenic and non-sarcopenic patients. |
| % of evolution of biomarkers | Day 1 / 5 years /10 years | Evaluate changes in plasma, serum, genetic and urinary biomarkers in the same population 5 and 10 years after the inclusion visit, and assess the relationship between changes in biomarkers and changes in sarcopenia using the biobank. |
Countries
France
Contacts
Primary ContactLise Laclautre
Outcome results
None listed